Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis.
Ostoros G, Hettle R, Georgoulia N, Berktas M, Chander P, Diaz Perez I, Couto AM, Eichinger C, Field P, Morten P. Ostoros G, et al. Among authors: hettle r. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(12):1305-1313. doi: 10.1080/14737140.2023.2272645. Epub 2023 Dec 8. Expert Rev Anticancer Ther. 2023. PMID: 37850939 Free article. Review.
Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.
Polyzoi M, Ekman M, Reithmeier A, Jacob J, Karlsson E, Bertranou E, Linderholm B, Hettle R. Polyzoi M, et al. Among authors: hettle r. Pharmacoecon Open. 2024 Mar;8(2):277-289. doi: 10.1007/s41669-023-00457-4. Epub 2023 Dec 13. Pharmacoecon Open. 2024. PMID: 38093030 Free PMC article.
Author response to 'Comment on "Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer" (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)'.
Hettle R, McCrea C. Hettle R, et al. Ther Adv Med Oncol. 2023 Apr 17;15:17588359231168519. doi: 10.1177/17588359231168519. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37113736 Free PMC article. No abstract available.
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P. Vergote I, et al. Among authors: hettle r. Eur J Cancer. 2021 Nov;157:415-423. doi: 10.1016/j.ejca.2021.08.023. Epub 2021 Sep 28. Eur J Cancer. 2021. PMID: 34597975 Free article. Clinical Trial.
34 results